Biocon Biologics to offer 15% stake to Serum Institute unit for access to vaccines By Reuters
BENGALURU (Reuters) – Biocon Biologics, a unit of drugmaker Biocon Ltd, mentioned late on Thursday it could supply a stake of about 15% to Serum Institute Life Sciences for entry to 100 million doses of vaccines yearly for 15 years, together with COVID-19 pictures.
The take care of the unit of Serum Institute of India (SII), the world’s largest vaccine maker, will worth Biocon Biologics at about $4.9 billion after deal shut, Biocon mentioned https://
As a part of the deal, Biocon Biologics and Serum Institute Life Sciences will make and distribute vaccines and antibodies. SII Chief Govt Officer Adar Poonawalla can even get a seat on the board of Biocon Biologics.
Biocon Ltd’s shares rose as a lot as 4.6% to 394.15 rupees on Friday.
Serum Institute didn’t present any further particulars on the deal when contacted by Reuters, whereas Biocon didn’t instantly reply to a request for remark. Each the businesses are scheduled to carry a press briefing later within the day.
Biocon Biologics partnered with U.S. primarily based Adagio Therapeutics in July to make and commercialise COVID-19 antibody remedies for India and a few rising markets.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or injury on account of reliance on the data together with knowledge, quotes, charts and purchase/promote alerts contained inside this web site. Please be totally knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is likely one of the riskiest funding types attainable.